WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics,...

Related Keywords

Germany ,Seoul ,Soult Ukpyolsi ,South Korea ,Shanghai ,China ,Wuxi ,Jiangsu ,Singapore ,Yuhan ,Anhui ,Ireland ,Chris Chen ,Immuneoncia Therapeutics Inc ,Sorrento Therapeutics Inc ,Yuhan Corporation , ,Wuxi Biologics ,Immuneoncia Therapeutics ,Wuxi Biologic ,Investigational New Drug ,Tae Kim ,Sorrento Therapeutics ,Greater China ,Hong Kong Listed ,